KRAS and non-small cell lung carcinoma: The development of KRAS G12C inhibitors, such as sotorasib and adagrasib, represent a modern revolution for patients with non-small-cell lung cancer (NSCLC) [54], but it should be acknowledged that this variant is very rare in PDAC (1%) [55].